On May 1, 2026, Arvinas, Inc. announced that the FDA approved VEPPANU™ for treating advanced breast cancer, which will generate a $50 million milestone payment from Pfizer. This is a significant event as VEPPANU is the first FDA-approved PROTAC protein degrader therapy for this condition.